Tysabri and Progressive Multifocal Leukoencephalopathy: Symptoms, Timeline, and Documentation
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Specific Exposure Risk
If you or a loved one has taken Tysabri and are experiencing new neurological symptoms—such as confusion, vision changes, or weakness on one side—it's important to understand the connection to progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established PML as a rare but serious adverse event associated with certain biologic therapies, including Tysabri. This page provides a clear overview of PML symptoms, the typical timeline of onset, and key steps for documenting your medical history.
Medical Risks and Clinical Presentation of PML
Tysabri (natalizumab) is a biologic therapy approved for the treatment of relapsing forms of multiple sclerosis (MS) and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV), which typically only occurs in immunocompromised individuals (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation varies but commonly includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis relies on brain imaging (MRI) showing characteristic white matter lesions, detection of JCV DNA in cerebrospinal fluid, and brain biopsy in ambiguous cases. Early recognition is critical because prompt withdrawal of Tysabri may improve outcomes, though many patients still suffer permanent disability.
Settlement-Related Considerations for Affected Patients
Patients who develop PML after Tysabri treatment may pursue legal claims based on inadequate warning or failure to mitigate risk. Settlement criteria typically consider the presence of anti-JCV antibodies, duration of therapy, and prior immunosuppressant use as documented risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between exposure and documented harm is critical: PML can occur after a variable period, with cases reported as early as eight doses and after longer treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Medical records should document the date of Tysabri initiation, duration of therapy, any prior immunosuppressant use, and the date of PML diagnosis. The severity of outcome—death or severe disability—is a key factor in settlement valuation. Additionally, evidence of compliance with monitoring recommendations (e.g., regular MRI, JCV antibody testing) may influence liability determinations.
Timeline Between Exposure and Documented Harm
In clinical trials, PML occurred after a median treatment duration of 120 weeks in MS patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data indicate that risk increases with longer exposure, especially beyond two years. The latency period from Tysabri initiation to PML onset can range from months to several years. Early detection through MRI and JCV testing may allow for intervention, but once neurological symptoms appear, the disease often progresses rapidly to severe disability or death.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Tysabri and why is it associated with PML?
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of immune suppression in the central nervous system (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What are the key risk factors for developing PML while on Tysabri?
What criteria are considered in Tysabri PML lawsuit settlements?
Settlement criteria typically include documented risk factors (anti-JCV antibodies, treatment duration, prior immunosuppressants), timeline from exposure to PML diagnosis, severity of outcome (death or severe disability), and evidence of compliance with monitoring recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.